Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Kynmobi

Apomorphine Hydrochloride

DiscontinuedRLDNDA 210875 5 strengths Sumitomo Pharma Am
Approved
May 21, 2020
Strengths
5
Listed patents
12

What does the FDA Orange Book show for Kynmobi?

Kynmobi contains Apomorphine Hydrochloride and is the new drug FDA Orange Book record for NDA 210875. The application has 5 presentations with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 210875

New drug application identity from the Orange Book snapshot.

Application holder
Sumitomo Pharma America Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
5

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Discontinued

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
12

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
00110MGFILMSUBLINGUALDiscontinuedNone posted
RLD
00215MGFILMSUBLINGUALDiscontinuedNone posted
RLD
00320MGFILMSUBLINGUALDiscontinuedNone posted
RLD
00425MGFILMSUBLINGUALDiscontinuedNone posted
RLD
00530MGFILMSUBLINGUALDiscontinuedNone posted
RLD

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Sumitomo Pharma America Inc

The Orange Book identifies this organization as the applicant responsible for NDA 210875.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

5 presentations listed as on the Discontinued Drug Product List

A discontinued-list entry does not, by itself, show why marketing stopped or whether FDA determined the product was withdrawn for safety or effectiveness.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

12 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Apr 19, 2036. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

1 other ANDA and 2 other NDAs found

1 of the related ANDA application is not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 210875 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Film · Sublingual

Apomorphine Hydrochloride

1 application
Product rows
5
Active applications
0
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-210875

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

5 approved presentations · NDA 210875
RLDDiscontinued
Strength
10MG
Dosage form
FILM
Route
SUBLINGUAL
Marketing status
Discontinued

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    6 yr 3 mo ago

  2. Today

  3. Patent 10821074 expires

    Listed drug product patent expiration.

    in 3 yr 1 mo

  4. Patent 10420763 expires

    Listed drug product patent expiration.

    in 3 yr 11 mo

  5. Patent 9044475 expires

    Listed drug product patent expiration.

    in 3 yr 11 mo

  6. Patent 9283219 expires

    Listed drug product patent expiration.

    in 3 yr 11 mo

  7. Patent 9326981 expires

    Listed method-of-use patent (U-2825) expiration.

    in 3 yr 11 mo

  8. Patent 9669019 expires

    Listed drug product patent expiration.

    in 3 yr 11 mo

  9. Patent 9669021 expires

    Listed method-of-use patent (U-2825) expiration.

    in 3 yr 11 mo

  10. Patent 11419769 expires

    Listed drug product patent expiration.

    in 5 yr 6 mo

  11. Patent 8414922 expires

    Listed drug product patent expiration.

    in 5 yr 6 mo

  12. Patent 8846074 expires

    Listed drug product patent expiration.

    in 5 yr 6 mo

  13. Patent 10449146 expires

    Listed method-of-use patent (U-2825) expiration.

    in 9 yr 11 mo

  14. Patent 10959943 expires

    Listed method-of-use patent (U-2825) expiration.

    in 9 yr 11 mo

Patent & exclusivity timeline

Protection horizon
202620282030203220342036TodayPatent 10821074: 2029-08-07Patent 10821074Patent 10420763: 2030-06-11Patent 10420763Patent 9044475: 2030-06-11Patent 9044475Patent 9283219: 2030-06-11Patent 9283219Patent 9326981: 2030-06-11Patent 9326981Patent 9669019: 2030-06-11Patent 9669019Patent 9669021: 2030-06-11Patent 9669021Patent 11419769: 2031-12-16Patent 11419769Patent 8414922: 2031-12-16Patent 8414922Patent 8846074: 2031-12-16Patent 8846074Patent 10449146: 2036-04-19Patent 10449146Patent 10959943: 2036-04-19Patent 10959943
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

APOMORPHINE HYDROCHLORIDE

Strength

10MG

Dosage form

FILM

Route

SUBLINGUAL

TE code

Not listed

Application

NDA 210875

Product number

001

Marketing status

Discontinued

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10821074in 3 yr 1 mo
Product
10420763in 3 yr 11 mo
ProductU-2825
9044475in 3 yr 11 mo
Product
9283219in 3 yr 11 mo
ProductU-2825
9326981in 3 yr 11 mo
U-2825
9669019in 3 yr 11 mo
ProductU-2825
9669021in 3 yr 11 mo
U-2825
11419769in 5 yr 6 mo
ProductU-2825
8414922in 5 yr 6 mo
ProductU-2825
8846074in 5 yr 6 mo
ProductU-2825
10449146in 9 yr 11 mo
U-2825
10959943in 9 yr 11 mo
U-2825

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Apomorphine Hydrochloride family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Kynmobi: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 210875 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo